Fig. 6.

Validation of the IRDS as a therapy-predictive marker for ADCT and/or radiation. Breast cancer patients from cohorts A, B, and C were used for validation of the IRDS (see Table S5). (A) Recurrence-free survival from metastasis and/or LRF as a first event for cohort A. All patients received ADCT and/or RT. (B) Patients who received ADCT and (C) patients who received adjuvant RT were separately analyzed for metastasis-free survival (MFS) or local-regional control, respectively. (D) MFS for cohort B, which received only endocrine therapy for adjuvant systemic treatment, and (E) MFS for cohort C, which received no adjuvant systemic therapy. (F) A merged set of 1,573 patients was used in a metaanalysis. Shown are bootstrap means ± SEs for the importance scores of the indicated covariates using either RSF or Cox regression models (see text and Fig. S7).